secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2026-04-07T23:59:59+00:00
Accession:  0001104659-26-040414
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec announces Univ of Arizona investigator-sponsored study of PEDMARK in AYA & adult cisplatin patients
--------------------------------------------------------------------------------

- Phase I/II study by University of Arizona Cancer Center to evaluate PEDMARK for preventing cisplatin-induced ototoxicity in head and neck and testicular cancer patients.
- Study builds on two other recent investigator-initiated trials: Tampa General Hospital (Mar 2026) and City of Hope (Dec 2025) in AYA and adult populations.
- Fennec CMO states data will support broader clinical adoption and potential label expansion for PEDMARK beyond pediatric approval.
- PEDMARK is currently approved for pediatric patients with localized non-metastatic solid tumors and has NCCN 2A recommendation for AYA patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926040414/0001104659-26-040414-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465926040414/fencf-20260407x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040414

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer